Please Wait a Moment
X

Articles

22Apr

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

22 Apr, 2020 | Return|

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV, and HCV), performed on the Tigris testing platform, to the newer Ultrio Elite triplex assay, and performed on the Panther testing platform. The CTS Phoenix lab will implement first on July 7th, with the 4 remaining CTS labs located in Charlotte, Dallas, St. Louis amd Tampa all implementing on July 13, 2020.

 

Click here for all the details: Communications

Related

CTS to Implement Donor HLA testing on the Stratec Gemini Instrument

On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...

Read More >

Bio-Rad Geenius HIV 1/2 Implementation

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...

Read More >

Notification of Form Revisions to Implement on September 2, 2019

The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- August 8th Update

CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...

Read More >

Procedure for pouring off samples if shipments will be extremely delayed

As winter weather continues to move through parts of the US, we would like to remind you it may be n...

Read More >